Manning Meredith 4

What Happened Meredith Manning, Chief Commercial Officer of Soleno Therapeutics (SLNO), sold a total of 7,522 shares on March 27, 2026 for aggregate proceeds of approximately $228,980. The sales were reported as open-market/private sales and were executed to satisfy tax-withholding obligations in connection with vested restricted stock units (RSUs).

Key Details

• Transactions (all 2026-03-27):
  • 4,864 shares at a weighted average price of $30.04 — proceeds $146,100 (multiple trades; prices ranged $29.54–$30.52).
  • 2,100 shares at a weighted average price of $31.04 — proceeds $65,181 (multiple trades; prices ranged $30.545–$31.41).
  • 558 shares at a weighted average price of $31.72 — proceeds $17,699 (multiple trades; prices ranged $31.64–$31.73).
• Total shares sold: 7,522; total proceeds: ~$228,980.
• Footnotes: Sales were to cover tax withholding for RSU vesting (F1). Some securities involved are RSUs (F3). Each sale was executed in multiple trades with price ranges and reported as weighted averages (F2, F4, F5).
• Shares owned after the transactions: not disclosed in this filing.
• Filing: Reported on 2026-03-31 — filed within the typical two-business-day Form 4 deadline for a 2026-03-27 transaction.

Context These sales were tax-withholding dispositions tied to RSU vesting (routine administrative transactions) rather than open-market purchases that might signal increased insider confidence. The filing shows sales (code "S") rather than purchases; for most retail investors, such withholding-related sales are considered routine and not necessarily indicative of the insider’s view on the company’s prospects.